Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

780 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Vilaprisan in women with uterine fibroids: the randomized phase 2b ASTEROID 1 study.
Bradley LD, Singh SS, Simon J, Gemzell-Danielsson K, Petersdorf K, Groettrup-Wolfers E, Ren X, Zvolanek M, Seitz C. Bradley LD, et al. Among authors: seitz c. Fertil Steril. 2019 Feb;111(2):240-248. doi: 10.1016/j.fertnstert.2018.10.012. Epub 2018 Dec 7. Fertil Steril. 2019. PMID: 30527839 Free article. Clinical Trial.
Rationale and design of ASTEROID 2, a randomized, placebo- and active comparator-controlled study to assess the efficacy and safety of vilaprisan in patients with uterine fibroids.
Seitz C, Bumbuliene Ž, Costa AR, Heikinheimo O, Heweker A, Hudeček R, Jacquemyn Y, Melis GB, Parashar P, Rechberger T, Sánchez AC, van Aken B, Zatik J, Gemzell-Danielsson K. Seitz C, et al. Contemp Clin Trials. 2017 Apr;55:56-62. doi: 10.1016/j.cct.2017.02.002. Epub 2017 Feb 6. Contemp Clin Trials. 2017. PMID: 28185997 Free article. Clinical Trial.
Efficacy and safety of vilaprisan in women with uterine fibroids: Data from the phase 2b randomized controlled trial ASTEROID 2.
Gemzell-Danielsson K, Heikinheimo O, Zatik J, Poka R, Rechberger T, Hudecek R, Petersdorf K, Ramirez F, Faustmann T, Groettrup-Wolfers E, Seitz C. Gemzell-Danielsson K, et al. Among authors: seitz c. Eur J Obstet Gynecol Reprod Biol. 2020 Sep;252:7-14. doi: 10.1016/j.ejogrb.2020.05.043. Epub 2020 May 31. Eur J Obstet Gynecol Reprod Biol. 2020. PMID: 32559602 Clinical Trial.
Assessment of the safe and efficacious dose of the selective progesterone receptor modulator vilaprisan for the treatment of patients with uterine fibroids by exposure-response modelling and simulation.
Sutter G, Frei M, Schultze-Mosgau MH, Petersdorf K, Seitz C, Ploeger BA. Sutter G, et al. Among authors: seitz c. Br J Clin Pharmacol. 2022 Feb;88(2):734-741. doi: 10.1111/bcp.15014. Epub 2021 Aug 25. Br J Clin Pharmacol. 2022. PMID: 34327754 Free PMC article.
A systematic review of methods to measure menstrual blood loss.
Magnay JL, O'Brien S, Gerlinger C, Seitz C. Magnay JL, et al. Among authors: seitz c. BMC Womens Health. 2018 Aug 22;18(1):142. doi: 10.1186/s12905-018-0627-8. BMC Womens Health. 2018. PMID: 30134884 Free PMC article.
Dienogest 2 mg Daily in the Treatment of Adolescents with Clinically Suspected Endometriosis: The VISanne Study to Assess Safety in ADOlescents.
Ebert AD, Dong L, Merz M, Kirsch B, Francuski M, Böttcher B, Roman H, Suvitie P, Hlavackova O, Gude K, Seitz C. Ebert AD, et al. Among authors: seitz c. J Pediatr Adolesc Gynecol. 2017 Oct;30(5):560-567. doi: 10.1016/j.jpag.2017.01.014. Epub 2017 Feb 9. J Pediatr Adolesc Gynecol. 2017. PMID: 28189702 Free article.
780 results